(Q93328984)

English

Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults

clinical trial

In more languages

default values for all languages

No label defined

No description defined

edit

Statements

instance of

clinical trial

0 references

title

A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults (English)

0 references

country

United States of America

0 references

Argentina

0 references

Brazil

0 references

main subject

Pfizer–BioNTech COVID-19 vaccine

1 reference

retrieved

12 July 2020

reference URL

https://covid-19tracker.milkeninstitute.org/

RNA vaccine

0 references

COVID-19

0 references

contributor to the creative work or subject

Pfizer

0 references

start time

28 April 2020

0 references

end time

27 January 2023

0 references

number of participants

29,481

0 references

research intervention

Pfizer–BioNTech COVID-19 vaccine

1 reference

retrieved

12 July 2020

reference URL

https://covid-19tracker.milkeninstitute.org/

clinical trial phase

phase I clinical trial

0 references

phase II clinical trial

0 references

phase III clinical trial

0 references

research subject recruitment status

recruiting

0 references

minimum age

18 year

0 references

maximum age

85 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT04368728

0 references

(Q93328984)

Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)